NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SION

Sionna Therapeutics Inc

May 12 • 04:00PM ET

12.90

Dollar change +0.58
Percentage change 4.71	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF SCHA SCHB VTWO VTWG VTWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	38.70%	Shs Outstand	44.12M	Perf Week	0.86%
Market Cap	569.15M	Forward P/E	-	EPS next Y	-2.46	Insider Trans	25.51%	Shs Float	27.05M	Perf Month	68.41%
Income	-	PEG	-	EPS next Q	-0.47	Inst Own	34.68%	Short Float	9.25%	Perf Quarter	-42.00%
Sales	-	P/S	-	EPS this Y	86.24%	Inst Trans	29.92%	Short Ratio	12.80	Perf Half Y	-
Book/sh	-3.71	P/B	-	EPS next Y	-11.93%	ROA	-	Short Interest	2.50M	Perf Year	-
Cash/sh	3.34	P/C	3.86	EPS next 5Y	44.50%	ROE	-	52W Range	7.26 - 25.19	Perf YTD	-48.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-48.79%	Beta	-
Dividend TTM	-	Quick Ratio	14.49	Sales past 5Y	0.00%	Gross Margin	-	52W Low	77.81%	ATR (14)	1.24
Dividend Ex-Date	-	Current Ratio	14.49	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	53.87	Volatility	7.41% 10.81%
Employees	41	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	38.50
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-	Payout	-	Rel Volume	0.74	Prev Close	12.32
Sales Surprise	-	EPS Surprise	-38.55%	Sales Q/Q	-	Earnings	May 12 BMO	Avg Volume	195.46K	Price	12.90
SMA20	7.78%	SMA50	3.08%	SMA200	-8.29%	Trades		Volume	143,757	Change	4.71%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-25	Initiated	TD Cowen	Buy
Mar-04-25	Initiated	Stifel	Buy	$32
Mar-04-25	Initiated	Guggenheim	Buy	$45

Today 07:00AM	Sionna Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-30-25 07:00AM	Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 (GlobeNewswire)
Mar-20-25 07:00AM	Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-15-25 04:43PM	Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:25AM	Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey) -5.04%
12:57PM	Loading…
Mar-03-25 12:57PM	Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-25-25 05:56AM	Sionna Therapeutics IPO: A strategic shift in the cystic fibrosis market (Pharmaceutical Technology) -13.37%
Feb-24-25 08:00AM	Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-17-25 04:43PM	Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:03PM	Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.04% -8.23%
Feb-06-25 07:51PM	Sionna Therapeutics Prices Upsized Initial Public Offering (GlobeNewswire)
03:13PM	Vertex challenger Sionna prices $191M IPO (BioPharma Dive)

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TPG GP A, LLC	10% Owner	Feb 10 '25	Buy	18.00	1,125,000	20,250,000	6,684,962	Feb 12 05:21 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 10 '25	Buy	18.00	1,125,000	20,250,000	6,923,365	Feb 10 05:04 PM
ORBIMED ADVISORS LLC	Director	Feb 10 '25	Buy	18.00	550,000	9,900,000	3,704,959	Feb 10 04:28 PM
Thompson Peter A.	Director	Feb 10 '25	Buy	18.00	550,000	9,900,000	3,704,959	Feb 10 04:05 PM
Booth Bruce	Director	Feb 10 '25	Buy	18.00	60,000	1,080,000	807,727	Feb 10 04:05 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 10 '25	Buy	18.00	60,000	1,080,000	807,727	Feb 10 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SION

Sionna Therapeutics Inc

Upgrade your FINVIZ experience